ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

9473	Companies
185423	Keywords
117773	Articles
99292	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 09/23/2025 at 22:30, 2 months 11 days ago

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court regarding a shareholder action and prepares for the General Meeting on September 30, 2025, ensuring transparency and commitment

Transparency General Meeting OSE Immunotherapeutics Shareholder Action Nantes Commercial Court
BRIEF

published on 08/29/2025 at 08:05, 3 months 7 days ago

OSE Immunotherapeutics Clarifies Strategy Amid Shareholder Activism

Strategic Priorities Legal Proceedings OSE Immunotherapeutics Shareholder Activism Tedopi® And Lusvertikimab
PRESS RELEASE

published on 08/29/2025 at 08:00, 3 months 7 days ago

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
OSE Immunotherapeutics reaffirms strategic priorities with comprehensive Q&A document ahead of AGM. Company focuses on Tedopi® and Lusvertikimab programs for value creation

Strategic Priorities OSE Immunotherapeutics Lusvertikimab Shareholder Q&A Tedopi®
BRIEF

published on 08/25/2025 at 07:05, 3 months 11 days ago

OSE Immunotherapeutics: New Governance and Strategic Objectives

Shareholders Biotechnology Governance Strategy Tedopi And Lusvertikimab
PRESS RELEASE

published on 08/25/2025 at 07:00, 3 months 11 days ago

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
OSE Immunotherapeutics announces proposed governance evolution and reaffirms strategic priorities ahead of Annual General Meeting. Company focuses on Tedopi® and Lusvertikimab to unlock full potential

Strategic Priorities Governance Evolution OSE Immunotherapeutics Lusvertikimab Tedopi
BRIEF

published on 08/20/2025 at 18:05, 3 months 15 days ago

OSE Immunotherapeutics Appoints Thomas Gidoin as CFO

Chief Financial Officer Strategic Planning Biotech Financing OSE Immunotherapeutics Thomas Gidoin
PRESS RELEASE

published on 08/20/2025 at 18:00, 3 months 15 days ago

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
OSE Immunotherapeutics appoints Thomas Gidoin as Chief Financial Officer, bringing deep expertise in capital markets and financial strategy to the company. Gidoin succeeds Anne-Laure Autret-Cornet

Chief Financial Officer Capital Markets Financial Strategy OSE Immunotherapeutics Thomas Gidoin
BRIEF

published on 07/02/2025 at 08:05, 5 months 3 days ago

OSE Immunotherapeutics Updates on Legal Proceedings

Transparency Shareholder Meeting Legal Proceedings OSE Immunotherapeutics Nantes Commercial Court
PRESS RELEASE

published on 07/02/2025 at 08:00, 5 months 3 days ago

OSE Immunotherapeutics met à jour l’information sur les procédures en cours
OSE Immunotherapeutics provides an update on ongoing legal proceedings regarding shareholders' motions, confirms plans for annual shareholders' meeting on September 30, 2025

Shareholders Biotech Annual Meeting Legal Proceedings OSE Immunotherapeutics
BRIEF

published on 06/20/2025 at 19:35, 5 months 14 days ago

OSE Immunotherapeutics secures its General Meeting

Shareholders Transparency General Assembly Legal Proceedings OSE Immunotherapeutics

Accesswire

Published on 12/05/2025 at 02:35, 7 hours 26 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 7 hours 31 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 9 hours 1 minute ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 56 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 11 hours 1 minute ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 09:40, 20 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 30 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 55 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 1 hour ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 09:00, 1 hour ago

SPECTRIS PLC - Removal

Les Echos

Published on 12/05/2025 at 08:45, 1 hour 16 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 16 hours 1 minute ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours 16 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours 16 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 3 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE